纤溶酶原激活物抑制剂-1与心血管疾病  

Plasminogen Activator Inhibitor-1 and Cardiovascular Diseases

作　　者：张冬梅[1] 陈明[1] 

机构地区：[1]重庆医科大学附属第一医院心内科,重庆400016

出　　处：《心血管病学进展》2009年第4期696-699,共4页Advances in Cardiovascular Diseases

摘　　要：纤溶酶原激活物抑制剂-1是纤溶系统的主要调节因子,通过抑制组织型纤溶酶原活化剂影响血浆纤溶和凝血系统的平衡,引起或者加速心血管疾病的发生发展。纤溶酶原激活物抑制剂-1对心血管疾病的诊断、预后,尤其对冠心病的诊断、分型、危险分层、预后及经皮冠状动脉介入治疗后的再狭窄的判断有重要指导意义。心血管疾病相关的的辅助检查中,纤溶酶原激活物抑制剂-1将提供一种新的选择。Plasminogen Activator Inhibitor-1 （ PAI-1 ） is a primary regulator of the fibrinolytic system. It is becoming a recognized risk factor in the development of cardiovascular diseases through its inhibition of the effects of t-PA. PAI-1 is also very important in the diagnosis and the risk stratification of coronary heart disease. PAI-1 may provide a new option in the auxiliary examination of cardiovascular diseases.

关 键 词：纤溶酶原激活物抑制剂-1 冠心病 原发性高血压 深静脉血栓形成 肺血栓栓塞 脑血栓形成 

分 类 号：R54[医药卫生—心血管疾病]